Company profile: Ibis Biosciences
1.1 - Company Overview
Company description
- Provider of products for the identification and characterization of infectious agents, including the Ibis T5000 Biosensor System, a hardware platform that identifies biological organisms such as bacteria, viruses, fungi and protozoa and provides information on drug resistance.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Ibis Biosciences
Antabio
HQ: France
Website
- Description: Provider of novel antibacterial resistance-breakers for drug-resistant infections, developing stand-alone inhibitors of bacterial metalloenzymes to restore antibiotic activity against critical pathogens; products include MEM-ANT3310 (meropenem + ANT3310, a serine-beta-lactamase inhibitor; targets CRAB and CRE), ANT3273 (inhaled for Pseudomonas aeruginosa), and ANT2681 (metallo β-lactamase inhibitor + meropenem for NDM CRE).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Antabio company profile →
Bluejay Diagnostics
HQ: United States
Website
- Description: Provider of the Symphony automated diagnostic system using fluorescence immuno-analysis for rapid testing with integrated reagents in single-use cartridges; Symphony cartridges for blood processing and ELISA of specific biomarkers; and the Symphony IL-6 test for near-patient monitoring of disease progression.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bluejay Diagnostics company profile →
Anacor Pharmaceuticals
HQ: United States
Website
- Description: Provider of small-molecule therapeutics based on a boron chemistry platform, focused on developing topical treatments for fungal, bacterial, and inflammatory diseases, including its primary product candidate AN2690, a novel topical antifungal.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Anacor Pharmaceuticals company profile →
T2 Biosystems
HQ: United States
Website
- Description: Provider of rapid, accurate infectious disease diagnostics, including the T2Dx Instrument, a fully automated system running tests directly from whole blood, the FDA-cleared T2Bacteria Panel for identifying sepsis-causing bacteria without blood culture, and T2Candida for detecting invasive candidiasis from whole blood.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full T2 Biosystems company profile →
Trimeris
HQ: United States
Website
- Description: Provider of HIV research and drug discovery, founded in 1993 in Morrisville, North Carolina, whose early work led to an entirely new class of anti-HIV drugs called fusion inhibitors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Trimeris company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Ibis Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Ibis Biosciences
2.2 - Growth funds investing in similar companies to Ibis Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Ibis Biosciences
4.2 - Public trading comparable groups for Ibis Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →